Trial Outcomes & Findings for Open-label Ziprasidone Study for Psychosis Treatment in Adolescents (NCT NCT00421954)
NCT ID: NCT00421954
Last Updated: 2017-01-13
Results Overview
Recruitment status
COMPLETED
Study phase
PHASE3
Target enrollment
8 participants
Primary outcome timeframe
couple of months
Results posted on
2017-01-13
Participant Flow
P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.
Participant milestones
| Measure |
Ziprasidone
Ziprasidone: subjects will use ziprasidone
|
|---|---|
|
Overall Study
STARTED
|
0
|
|
Overall Study
COMPLETED
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Open-label Ziprasidone Study for Psychosis Treatment in Adolescents
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: couple of monthsPopulation: P.I. has left the institution and NYSPI has no access to the data. Results will not be analyzed or presented.
Outcome measures
Outcome data not reported
Adverse Events
Ziprasidone
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place